摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[(2S,3S,4R)-1-[(2S,3R,4S,5R,6R)-6-[(4,5-diphenyltriazol-1-yl)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]hexacosanamide | 1383455-86-4

中文名称
——
中文别名
——
英文名称
N-[(2S,3S,4R)-1-[(2S,3R,4S,5R,6R)-6-[(4,5-diphenyltriazol-1-yl)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]hexacosanamide
英文别名
——
N-[(2S,3S,4R)-1-[(2S,3R,4S,5R,6R)-6-[(4,5-diphenyltriazol-1-yl)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]hexacosanamide化学式
CAS
1383455-86-4
化学式
C64H108N4O8
mdl
——
分子量
1061.58
InChiKey
RJAAWPVKQHFJKC-RUKSZLDWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    18.9
  • 重原子数:
    76
  • 可旋转键数:
    47
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.77
  • 拓扑面积:
    179
  • 氢给体数:
    6
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (2S,3S,4R)-1-(6-deoxy-6-azido-α-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecandiol二苯基乙炔二(三苯基膦)环戊二烯基氯化钌(II) 作用下, 以 四氢呋喃 为溶剂, 反应 3.0h, 以72%的产率得到N-[(2S,3S,4R)-1-[(2S,3R,4S,5R,6R)-6-[(4,5-diphenyltriazol-1-yl)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]hexacosanamide
    参考文献:
    名称:
    New CD1d agonists: Synthesis and biological activity of 6″-triazole-substituted α-galactosyl ceramides
    摘要:
    Huisgen [3+2] dipolar cycloaddition of 6 ''-azido-6 ''-deoxy-alpha-galactosyl ceramide 11 with a range of alkynes (or a benzyne precursor) yielded a series of triazole-containing alpha-galactosyl ceramide (alpha-GalCer) analogues in high yield. These alpha-GalCer analogues and the precursor azide 11 were tested for their ability to activate iNKT cells and stimulate IL-2 cytokine secretion in vitro, and IFN-gamma and IL-4 cytokine secretion in vivo. Some of these analogues, specifically 11, 12b, 12f and 13, were more potent IL-2 stimulators than the prototypical CD1d agonist, alpha-GalCer 1. In terms of any cytokine bias, most of the triazole-containing analogues exhibited a small Th2 cytokine-biasing response relative to that shown by alpha-GalCer 1. In contrast, the cycloaddition precursor, namely azide 11, provided a small Th1 cytokine-biasing response. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.05.009
点击查看最新优质反应信息

文献信息

  • New CD1d agonists: Synthesis and biological activity of 6″-triazole-substituted α-galactosyl ceramides
    作者:Peter J. Jervis、Lisa M. Graham、Erin L. Foster、Liam R. Cox、Steven A. Porcelli、Gurdyal S. Besra
    DOI:10.1016/j.bmcl.2012.05.009
    日期:2012.7
    Huisgen [3+2] dipolar cycloaddition of 6 ''-azido-6 ''-deoxy-alpha-galactosyl ceramide 11 with a range of alkynes (or a benzyne precursor) yielded a series of triazole-containing alpha-galactosyl ceramide (alpha-GalCer) analogues in high yield. These alpha-GalCer analogues and the precursor azide 11 were tested for their ability to activate iNKT cells and stimulate IL-2 cytokine secretion in vitro, and IFN-gamma and IL-4 cytokine secretion in vivo. Some of these analogues, specifically 11, 12b, 12f and 13, were more potent IL-2 stimulators than the prototypical CD1d agonist, alpha-GalCer 1. In terms of any cytokine bias, most of the triazole-containing analogues exhibited a small Th2 cytokine-biasing response relative to that shown by alpha-GalCer 1. In contrast, the cycloaddition precursor, namely azide 11, provided a small Th1 cytokine-biasing response. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多